* Relay Therapeutics Inc RLAY.OQ RLAY.O is expected
to show a
rise in quarterly revenue when it reports results on August 2
(estimated).
* The Cambridge Massachusetts-based company is expected to
report
a 104.9% increase in revenue to $747.78 thousand from $365
thousand a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Relay Therapeutics
Inc is
for a loss of 81 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Relay
Therapeutics Inc is $29, above its last closing price
of $12.60.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.66 -0.69 -0.78 Missed -12.8
Dec. 31 2023 -0.71 -0.70 -0.56 Beat 20.3
Sep. 30 2022 -0.72 -0.71 -0.76 Missed -7.7
Jun. 30 2022 -0.63 -0.63 -0.71 Missed -13
Mar. -0.62 -0.62 -0.57 Beat 7.8
31 2022
Dec. 31 2021 -0.57 -0.58 -0.62 Missed -7.2
Sep. 30 2021 -0.65 -0.64 -0.66 Missed -3.4
Jun. 30 2021 -0.44 -0.46 -2.10 Missed -360.8
This summary was machine generated August 1 at 01:23 GMT. All
figures in US dollars unless otherwise stated